drugset / Trial / NCT07288216
Transition to KPL-387 Monotherapy Dosing & Administration Study
Phase 2
Recruiting
80 enrolled
Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals, Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.
Timeline
- Start
- 2026-03-25
- Primary completion
- 2027-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KPL-387 | Unknown | — | Subcutaneous |